FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904267905> ?p ?o ?g. }

• W2904267905 endingPage "911" @default.
• W2904267905 startingPage "904" @default.
• W2904267905 abstract "To improve complete remission (CR) rates by reducing toxicity and enhancing delivery, we created a modified hyper-CVAD/MA regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine) by reducing the cytarabine dose (3 g/m2 to 2 g/m2) and number of cycles (eight to six). We conducted a phase II trial in the pre-rituximab era in the intermediate–high international prognostic index (IPI) (≥2) de novo diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) (ACTRN12605000105640). CR rates were compared with reported IPI-stratified rates. Sixty-three patients (n = 26 PTCL; n = 37 DLBCL) were evaluated; median follow-up of 30 months. CR rates for PTCL and DLBCL patients were 46% and 49%, respectively, similar with reported CR rates with CHOP-like chemotherapy (p = .6). Of the patients, 51 (81%) experienced ≥1 unplanned hospital admission; only 41 (65%) completed six cycles. The cytarabine modifications did not prevent significant toxicity. Modified hyper-CVAD/MA resulted in similar outcomes to CHOP-like chemotherapy in aggressive lymphomas and was associated with significant toxicity." @default.
• W2904267905 created "2018-12-22" @default.
• W2904267905 creator A5007139079 @default.
• W2904267905 creator A5018291468 @default.
• W2904267905 creator A5031193094 @default.
• W2904267905 creator A5034141452 @default.
• W2904267905 creator A5059015775 @default.
• W2904267905 creator A5066166932 @default.
• W2904267905 creator A5069338863 @default.
• W2904267905 creator A5071255453 @default.
• W2904267905 creator A5080144419 @default.
• W2904267905 creator A5081326206 @default.
• W2904267905 creator A5082085036 @default.
• W2904267905 date "2018-12-14" @default.
• W2904267905 modified "2023-09-26" @default.
• W2904267905 title "A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma" @default.
• W2904267905 cites W1783838151 @default.
• W2904267905 cites W1832431868 @default.
• W2904267905 cites W1862517694 @default.
• W2904267905 cites W1875404032 @default.
• W2904267905 cites W1881397173 @default.
• W2904267905 cites W1912693401 @default.
• W2904267905 cites W1913594340 @default.
• W2904267905 cites W1933973263 @default.
• W2904267905 cites W1983084203 @default.
• W2904267905 cites W2058015212 @default.
• W2904267905 cites W2058767673 @default.
• W2904267905 cites W2072351874 @default.
• W2904267905 cites W2074552386 @default.
• W2904267905 cites W2081238814 @default.
• W2904267905 cites W2098666639 @default.
• W2904267905 cites W2100090512 @default.
• W2904267905 cites W2106928992 @default.
• W2904267905 cites W2111322227 @default.
• W2904267905 cites W2111827890 @default.
• W2904267905 cites W2125684345 @default.
• W2904267905 cites W2131338392 @default.
• W2904267905 cites W2137348614 @default.
• W2904267905 cites W2144002645 @default.
• W2904267905 cites W2145164152 @default.
• W2904267905 cites W2146456594 @default.
• W2904267905 cites W2153569820 @default.
• W2904267905 cites W2160009753 @default.
• W2904267905 cites W2160305510 @default.
• W2904267905 cites W2164995655 @default.
• W2904267905 cites W2171356556 @default.
• W2904267905 cites W2318772898 @default.
• W2904267905 cites W4205736005 @default.
• W2904267905 cites W70385801 @default.
• W2904267905 doi "https://doi.org/10.1080/10428194.2018.1516873" @default.
• W2904267905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30547695" @default.
• W2904267905 hasPublicationYear "2018" @default.
• W2904267905 type Work @default.
• W2904267905 sameAs 2904267905 @default.
• W2904267905 citedByCount "8" @default.
• W2904267905 countsByYear W29042679052019 @default.
• W2904267905 countsByYear W29042679052021 @default.
• W2904267905 countsByYear W29042679052022 @default.
• W2904267905 countsByYear W29042679052023 @default.
• W2904267905 crossrefType "journal-article" @default.
• W2904267905 hasAuthorship W2904267905A5007139079 @default.
• W2904267905 hasAuthorship W2904267905A5018291468 @default.
• W2904267905 hasAuthorship W2904267905A5031193094 @default.
• W2904267905 hasAuthorship W2904267905A5034141452 @default.
• W2904267905 hasAuthorship W2904267905A5059015775 @default.
• W2904267905 hasAuthorship W2904267905A5066166932 @default.
• W2904267905 hasAuthorship W2904267905A5069338863 @default.
• W2904267905 hasAuthorship W2904267905A5071255453 @default.
• W2904267905 hasAuthorship W2904267905A5080144419 @default.
• W2904267905 hasAuthorship W2904267905A5081326206 @default.
• W2904267905 hasAuthorship W2904267905A5082085036 @default.
• W2904267905 hasConcept C126322002 @default.
• W2904267905 hasConcept C141071460 @default.
• W2904267905 hasConcept C143998085 @default.
• W2904267905 hasConcept C2776694085 @default.
• W2904267905 hasConcept C2776755627 @default.
• W2904267905 hasConcept C2778041864 @default.
• W2904267905 hasConcept C2778476033 @default.
• W2904267905 hasConcept C2778559949 @default.
• W2904267905 hasConcept C2779338263 @default.
• W2904267905 hasConcept C2779429289 @default.
• W2904267905 hasConcept C2779725641 @default.
• W2904267905 hasConcept C2780653079 @default.
• W2904267905 hasConcept C2781413609 @default.
• W2904267905 hasConcept C71924100 @default.
• W2904267905 hasConcept C90924648 @default.
• W2904267905 hasConceptScore W2904267905C126322002 @default.
• W2904267905 hasConceptScore W2904267905C141071460 @default.
• W2904267905 hasConceptScore W2904267905C143998085 @default.
• W2904267905 hasConceptScore W2904267905C2776694085 @default.
• W2904267905 hasConceptScore W2904267905C2776755627 @default.
• W2904267905 hasConceptScore W2904267905C2778041864 @default.
• W2904267905 hasConceptScore W2904267905C2778476033 @default.
• W2904267905 hasConceptScore W2904267905C2778559949 @default.
• W2904267905 hasConceptScore W2904267905C2779338263 @default.
• W2904267905 hasConceptScore W2904267905C2779429289 @default.
• W2904267905 hasConceptScore W2904267905C2779725641 @default.
• W2904267905 hasConceptScore W2904267905C2780653079 @default.

• next